COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used for both adults and children. The vaccines can be broadly classified into prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of the disease. Mordor Intelligence analysis forecasts the global cancer vaccines market to grow at a CAGR of 12-18% over the period 2015-2020. It is currently estimated to be valued at USD 2.1 billion for the year 2015.

The market for cancer vaccines is much smaller than other cancer therapeutic categories. The size of the market can be attributed to the nascent stages of industry life cycle and the late introduction of the vaccines in the market. To tap this market, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the increase in competition among the various pharmaceutical companies to obtain a larger portion of this market.

The Global Cancer Vaccines Market is segmented based on:


Subunit Vaccines

Live Attenuated Vaccines

Conjugate Vaccines

Inactivated Vaccines

Recombinant Vector Vaccines

Toxoid Vaccines

Synthetic Vaccines

Dendritic Cell Vaccines


Preventive Vaccines

Therapeutic Vaccines

Disease Indication

Cervical cancer


End user




North America


Latin America

Middle East and Africa

Asia Pacific

According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers.

North America dominates the market, with the U.S. accounting for a major market share. However, Asia is poised to grow at the highest CAGR during the forecast period owing to the governmental initiatives, rising focus of major players on the Indian vaccine technology market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.

Some of the key participants in the industry include Prima BioMed, GlaxoSmithKline, Sanofi S.A, Merck, Aduro BioTech, AstraZeneca plc, OXFORD BIOMEDICA etc.


Increasing cancer cases

Technological developments

Drug innovations with regard to the cancer

Government initiatives

Rise in aging populace

Advanced health care services

Upsurge in awareness about cancer and their available therapies in the market

Increasing health care expenditure


Cold chain, or temperature-controlled supply chain, management

Low accessibility to vaccines in remote areas

Stringent regulatory procedures